NI biosecurity firm Ilimex raises €700,000 seed round to tackle avian flu

Northern Ireland-based biosecurity start-up Ilimex has successfully raised €700,000 in a seed funding round to advance its work on combating airborne pathogens and viruses, including avian flu. The capital injection will support the company's development of innovative solutions aimed at addressing the challenges posed by disruptive diseases such as avian influenza. Ilimex's focus on biosecurity highlights the growing importance of technologies designed to detect and mitigate airborne health threats. This funding milestone marks a significant step for the start-up as it seeks to expand its capabilities and impact in the field of pathogen control. The €700,000 seed round demonstrates investor confidence in Ilimex's approach and potential to contribute to public health and safety. As avian flu continues to pose risks globally, the company's efforts align with broader efforts to enhance disease prevention and biosecurity measures.